Terms: = Lung cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR
640 results:
1. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
2. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell lung cancer.
Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence of metastases outside the liver and abdominal lymph nodes on
Wedin M; Janson ET; Wallin G; Sundin A; Daskalakis K
J Neuroendocrinol; 2024 May; 36(5):e13391. PubMed ID: 38590270
[TBL] [Abstract] [Full Text] [Related]
4. The new N
Liu J; Nie W; Nie H; Yao H; Ren Y; Cao L; Qiu J; Wang M; Li X; An B; Jia X
Bioorg Chem; 2024 May; 146():107313. PubMed ID: 38554675
[TBL] [Abstract] [Full Text] [Related]
5. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Leonetti A; Perrone F; Puntoni M; Maglietta G; Bordi P; Bria E; Vita E; Gelsomino F; De Giglio A; Gelibter A; Siringo M; Mazzoni F; Caliman E; Genova C; Bertolini F; Guaitoli G; Passiglia F; Delcuratolo MD; Montrone M; Cerea G; Pasello G; Roca E; Belluomini L; Cecere FL; Guida A; Manzo A; Adamo V; Rastelli F; Bulotta A; Citarella F; Toschi L; Zoratto F; Cortinovis DL; Berardi R; Follador A; Carta A; Camerini A; Salerno F; Silva RR; Baldini E; Cortellini A; Brighenti M; Santoni M; Malorgio F; Caminiti C; Tiseo M
Eur J Cancer; 2024 May; 202():114006. PubMed ID: 38489861
[TBL] [Abstract] [Full Text] [Related]
6. Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.
Nofal S; Niu J; Resong P; Jin J; Merriman KW; Le X; Katki H; Heymach J; Antonoff MB; Ostrin E; Wu J; Zhang J; Toumazis I
Cancer Med; 2024 Mar; 13(5):e7069. PubMed ID: 38466021
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of Microwave Ablation Recurrence in Pulmonary Malignancies Using Preoperative Computed Tomography Radiomics Models.
Zhu F; Yang C; Yang J; Mao H; Huang Y; Liu H; Zhao Z
Curr Med Imaging; 2024; 20():1-26. PubMed ID: 38389378
[TBL] [Abstract] [Full Text] [Related]
8. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Zhao Y; Mei T; Na F; Tian X; Ao R; Long X; Luo Q; Duan P; Zhu J; Wang Y; Huang M; Liu Y; Gong Y
Invest New Drugs; 2024 Apr; 42(2):196-206. PubMed ID: 38386170
[TBL] [Abstract] [Full Text] [Related]
9. Accelerometer-Measured Physical Activity, Sedentary Time, and Heart Failure Risk in Women Aged 63 to 99 Years.
LaMonte MJ; LaCroix AZ; Nguyen S; Evenson KR; Di C; Stefanick ML; Hyde ET; Anuskiewicz B; Eaton CB
JAMA Cardiol; 2024 Apr; 9(4):336-345. PubMed ID: 38381446
[TBL] [Abstract] [Full Text] [Related]
10. Factors affecting accuracy of clinical staging in resectable non-small cell lung cancer in a real-world study.
Gwon HR; La Woo A; Yong SH; Park Y; Kim SY; Kim EY; Jung JY; Kang YA; Park MS; Park SY; Lee SH
Thorac Cancer; 2024 Mar; 15(9):730-737. PubMed ID: 38380557
[TBL] [Abstract] [Full Text] [Related]
11. Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis.
Oliveira C; Mainoli B; Duarte GS; Machado T; Tinoco RG; Esperança-Martins M; Ferreira JJ; Costa J
Eur J Clin Pharmacol; 2024 May; 80(5):677-684. PubMed ID: 38372756
[TBL] [Abstract] [Full Text] [Related]
12. MIHIC: a multiplex IHC histopathological image classification dataset for lung cancer immune microenvironment quantification.
Wang R; Qiu Y; Wang T; Wang M; Jin S; Cong F; Zhang Y; Xu H
Front Immunol; 2024; 15():1334348. PubMed ID: 38370413
[TBL] [Abstract] [Full Text] [Related]
13. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
14. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract] [Full Text] [Related]
15. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
16. Multimorbidity clusters in adults 50 years or older with and without a history of cancer: National Health Interview Survey, 2018.
Plasencia G; Gray SC; Hall IJ; Smith JL
BMC Geriatr; 2024 Jan; 24(1):50. PubMed ID: 38212690
[TBL] [Abstract] [Full Text] [Related]
17. Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland.
Putila E; Helminen O; Helmiö M; Huhta H; Jalkanen A; Kallio R; Koivukangas V; Kokkola A; Laine S; Lietzen E; Louhimo J; Meriläinen S; Pohjanen VM; Rantanen T; Junttila A; Ristimäki A; Räsänen JV; Saarnio J; Sihvo E; Toikkanen V; Tyrväinen T; Valtola A; Kauppila JH;
Ann Surg Oncol; 2024 Apr; 31(4):2689-2698. PubMed ID: 38153640
[TBL] [Abstract] [Full Text] [Related]
18. Occupational-related exposure to diesel exhaust and risk of leukemia: systematic review and meta-analysis of cohort studies.
Shah D; DeStefano V; Collatuzzo G; Teglia F; Boffetta P
Int Arch Occup Environ Health; 2024 Mar; 97(2):165-177. PubMed ID: 38142415
[TBL] [Abstract] [Full Text] [Related]
19. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.
Zhang S; Yan J; He L; Jiang Z; Jiang H
Cancer Gene Ther; 2024 Mar; 31(3):484-494. PubMed ID: 38135698
[TBL] [Abstract] [Full Text] [Related]
20. Developing a multi-institutional nomogram for assessing lung cancer risk in patients with 5-30 mm pulmonary nodules: a retrospective analysis.
Jiang Y; Deng T; Huang Y; Ren B; He L; Pang M; Jiang L
PeerJ; 2023; 11():e16539. PubMed ID: 38107565
[TBL] [Abstract] [Full Text] [Related]
[Next]
